Abstract: The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respiratory diseases comprising 2-hydroxybenzoic acid derivatives of the formula (I) or a pharmaceutically acceptable salt thereof. Administration of a 2-hydroxybenzoic acid derivative of formula (I) significantly alleviates airway tissue damage and inflammation in animal models of asthma and COPD.

Abstract: An etching gas mixture includes a nitrogen-containing compound and an inert gas. To manufacture an integrated circuit (IC) device, a silicon-containing film on a substrate is etched by using plasma generated from the etching gas mixture, and thus a hole is formed in the silicon-containing film. The nitrogen-containing compound is selected from a compound represented by Formula 1 and a compound represented by Formula 2: (R1)C?N ??[Formula 1] wherein in Formula 1, R1 is a C2 to C3 linear or branched perfluoroalkyl group, (R2)(R3)C?NH tm [Formula 2] wherein in Formula 2, each of R2 and R3 is independently a C1 to C2 linear perfluoroalkyl group.

Abstract: An etching gas mixture includes a nitrogen-containing compound and an inert gas. To manufacture an integrated circuit (IC) device, a silicon-containing film on a substrate is etched by using plasma generated from the etching gas mixture, and thus a hole is formed in the silicon-containing film. The nitrogen-containing compound is selected from a compound represented by Formula 1 and a compound represented by Formula 2: (R1)C?N ??[Formula 1] wherein in Formula 1, R1 is a C2 to C3 linear or branched perfluoroalkyl group, (R2)(R3)C?NH ??[Formula 2] wherein in Formula 2, each of R2 and R3 is independently a C1 to C2 linear perfluoroalkyl group.

Abstract: The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respiratory diseases comprising 2-hydroxybenzoic acid derivatives of the formula (I) or a pharmaceutically acceptable salt thereof. Administration of a 2-hydroxybenzoic acid derivative of formula (I) significantly alleviates airway tissue damage and inflammation in animal models of asthma and COPD.

Abstract: An etching gas mixture includes a nitrogen-containing compound and an inert gas. To manufacture an integrated circuit (IC) device, a silicon-containing film on a substrate is etched by using plasma generated from the etching gas mixture, and thus a hole is formed in the silicon-containing film. The nitrogen-containing compound is selected from a compound represented by Formula 1 and a compound represented by Formula 2: (R1)C?N ??[Formula 1] wherein in Formula 1, R1 is a C2 to C3 linear or branched perfluoroalkyl group, (R2)(R3)C?NH ??[Formula 2] wherein in Formula 2, each of R2 and R3 is independently a C1 to C2 linear perfluoroalkyl group.

Abstract: The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respiratory diseases comprising 2-hydroxybenzoic acid derivatives of the formula (I) or a pharmaceutically acceptable salt thereof. Administration of a 2-hydroxybenzoic acid derivative of formula (I) significantly alleviates airway tissue damage and inflammation in animal models of asthma and COPD.

Abstract: A pellicle for a reflective mask includes a pellicle body, a pellicle frame below the pellicle body to support the pellicle body, and a pattern structure in at least a part of a surface of the pellicle body, wherein the pattern structure includes a plurality of patterns.

Abstract: The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

Abstract: Optically transparent, highly conductive conductor materials are provided, which in certain variations may also be flexible. Methods of making transparent conductive conductors, such as electrodes, are also provided. Such a method may include creating a groove pattern on a substrate that defines a two-dimensional array. Then an electrically conductive material may be selectively applied within the groove pattern of the substrate so as to create a transparent conductor (e.g., a transparent conductive electrode (TCE)). The transparent conductor has a sheet resistance of ?about 5 Ohms/Square and a transmissivity of ?about 50% for a predetermined range of target wavelengths of electromagnetic energy. Such methods may form linear micromesh conductive arrays and tortuous micromesh conductive arrays that can be used in a variety of optoelectronic applications, including as optically transparent, flexible and mechanically reconfigurable zeroth-order resonant (ZOR) antennas.

Abstract: An apparatus for removing residues from a source vessel in an extreme ultraviolet lithography device, the apparatus including a frame portion, and a heater structure on the frame portion, the heater structure having a head on the frame portion, the head being rotatable in at least one shaft direction, and a heater on the head to dissipate heat toward residues in the source vessel, the heater to apply temperature of 200° C. to 800° C.

Abstract: A pellicle for a reflective mask includes a pellicle body, a pellicle frame below the pellicle body to support the pellicle body, and a pattern structure in at least a part of a surface of the pellicle body, wherein the pattern structure includes a plurality of patterns.

Abstract: A mobile terminal having a terminal main body including a front case forming an internal area including a submergence area into which water is introduced and a waterproof area into which water is blocked from being introduced, and an internal frame; a first unit including a key module mounted in the terminal main body, and generating a control command when a pressing occurs, the key module being positioned in the submergence area and moving due to an external force; a second unit positioned in the waterproof area, and when the pressing occurs, generates a signal; an elastic deformation layer of which a portion is elastically deformed due to movement of the first unit, so the second unit is pressed by the first unit; and a waterproof layer attaching the elastic deformation layer and the front case so partitioning results in the submergence area and the waterproof area.

Abstract: An apparatus for removing residues from a source vessel in an extreme ultraviolet lithography device, the apparatus including a frame portion, and a heater structure on the frame portion, the heater structure having a head on the frame portion, the head being rotatable in at least one shaft direction, and a heater on the head to dissipate heat toward residues in the source vessel, the heater to apply temperature of 200° C. to 800° C.

Abstract: A substrate manufacturing apparatus includes a test apparatus including a test handler module for performing a test process on a substrate. The test handler module may include a conveyor unit to transfer a substrate, a handler unit for performing a test process on the substrate, and a transfer unit for transferring the substrate between the conveyor unit and the handler unit. The conveyor unit may include a feed conveyor and a discharge conveyor spaced apart from the feed conveyor.

Abstract: The present disclosure relates to pharmaceutical compositions for treating cognitive decline in companion animals, comprising a 5-benzylaminosalicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, e.g., suitable for oral administration. Compositions comprising the 5-benzylamino salicylic acid compound of formula (I), or a pharmaceutically acceptable salt thereof can be used to treat progressive cognitive disorder in neurological diseases including cognitive dysfunction syndrome (CDS), dysthymia, involutive depression, and confusional syndrome in aging companion animals.

Abstract: The present invention provides a mobile terminal comprising: a terminal main body comprising a front case and an internal frame forming an internal area including an inundation area in which terminal water flows in and a waterproof area in which the inflow of water is blocked; and a key module mounted on the terminal main body and forming, by pressing, a control command, wherein the key module comprises: a first unit disposed in the inundation area and moved by an external force; a second unit disposed in the waterproof area and a signal generated by pressing; an elastic deformation layer having one region elastically deformed by movement of the first unit such that the second unit is pressed by the first unit; and a through hole, which allows the elastic deformation layer and the front case to be attached so as to partition the inundation area and the waterproof area and through which the first unit penetrates.

Abstract: The present invention relates to a case assembly for a mobile terminal. The case assembly according to an aspect includes a rear surface case detachably coupled to a rear surface of a terminal body to cover the rear surface of the terminal body, a rear cover coupled to a rear surface of the rear surface case to protect the rear surface of the rear surface case, and an adhesive sheet provided between the rear surface case and the rear cover to provide an adhesive force to opposite surfaces so as to couple the rear cover to the rear surface of the rear surface case, wherein adhesive parts configured to couple the rear cover and the rear surface case to each other along an edge of the rear surface case are formed in the edge of the rear surface case and an area of the rear cover, which covers the edge of the rear surface case.

Abstract: Optically transparent, highly conductive conductor materials are provided, which in certain variations may also be flexible. Methods of making transparent conductive conductors, such as electrodes, are also provided. Such a method may include creating a groove pattern on a substrate that defines a two-dimensional array. Then an electrically conductive material may be selectively applied within the groove pattern of the substrate so as to create a transparent conductor (e.g., a transparent conductive electrode (TCE)). The transparent conductor has a sheet resistance of ?about 5 Ohms/Square and a transmissivity of ?about 50% for a predetermined range of target wavelengths of electromagnetic energy. Such methods may form linear micromesh conductive arrays and tortuous micromesh conductive arrays that can be used in a variety of optoelectronic applications, including as optically transparent, flexible and mechanically reconfigurable zeroth-order resonant (ZOR) antennas.

Abstract: A substrate manufacturing apparatus includes a test apparatus including a test handler module for performing a test process on a substrate. The test handler module may include a conveyor unit to transfer a substrate, a handler unit for performing a test process on the substrate, and a transfer unit for transferring the substrate between the conveyor unit and the handler unit. The conveyor unit may include a feed conveyor and a discharge conveyor spaced apart from the feed conveyor.

Abstract: A substrate manufacturing apparatus includes a test apparatus including a test handler module for performing a test process on a substrate. The test handler module may include a conveyor unit to transfer a substrate, a handler unit for performing a test process on the substrate, and a transfer unit for transferring the substrate between the conveyor unit and the handler unit. The conveyor unit may include a feed conveyor and a discharge conveyor spaced apart from the feed conveyor.